DWAS - ETF AI Analysis
Top Page
Invesco DWA SmallCap Momentum ETF (DWAS)
DWAS, the Invesco DWA SmallCap Momentum ETF, has a solid overall rating driven by several strong momentum and growth names like Sezzle and Bel Fuse, which show robust financial performance, bullish technical trends, and positive earnings sentiment. However, early-stage and financially challenged holdings such as Erasca, Climb Bio, and Agilon Health, with losses, bearish trends, or declining revenues, weigh on the fund’s quality. The main risk factor is its exposure to multiple high-risk small-cap and early-stage companies, especially in areas like biotech, which can increase volatility and downside risk.
DWAS vs. SPDR S&P 500 ETF (SPY)
- AUM
- 388.57M
- Region
- North America
- Expense Ratio
- 0.60%
- Beta
- 1.18
- Issuer
- Invesco
- Inception Date
- Jul 19, 2012
- Dividend Yield
- 0.03%
- Asset Class
- Equity
- Index Tracked
- Dorsey Wright SmallCap Tech Leaders Index
DWAS Summary
The Invesco DWA SmallCap Momentum ETF (DWAS) is a fund that tracks the Dorsey Wright SmallCap Technical Leaders Index, focusing on smaller U.S. companies whose stock prices have been rising strongly. It spreads investments across many areas like health care, technology, and industrials, with holdings such as Agilon Health and Amneal Pharmaceuticals. Someone might invest in DWAS to seek higher growth by targeting small companies with strong recent performance and to diversify beyond large, well-known stocks. However, small-cap momentum stocks can be very volatile, so the price of this ETF can move up and down sharply.
How much will it cost me?
The Invesco DWA SmallCap Momentum ETF (DWAS) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on small-cap stocks with strong momentum, which requires more research and management compared to passively managed ETFs. It’s designed for investors seeking growth opportunities in dynamic, smaller companies.
What would affect this ETF?
The DWAS ETF, focused on U.S. small-cap stocks with strong momentum, could benefit from economic growth and innovation in sectors like Health Care and Technology, which make up a significant portion of its holdings. However, it may face challenges during periods of economic uncertainty or rising interest rates, which can negatively impact small-cap companies and momentum-driven strategies. Regulatory changes or sector-specific headwinds could also influence the performance of its top holdings.
DWAS Top 10 Holdings
DWAS is riding a classic small-cap momentum wave, with U.S. names like Frequency Electronics and Amneal Pharmaceuticals helping power returns as their stocks keep climbing. On the tech side, AXT and Aehr Test Systems add a semiconductor-flavored tilt, though Aehr’s story is more mixed as operational challenges cap its upside. Health care is a big swing factor: early-stage biotechs like Erasca and Tango Therapeutics bring high-octane potential but also inject volatility, sometimes dragging on results. Overall, the fund leans heavily into U.S. small-cap health care and tech risk for its momentum edge.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AMRX | Amneal Pharmaceuticals | 1.64% | $6.40M | $6.34B | 96.36% | 58Neutral |
 AAMI | Acadian Asset Management | 1.48% | $5.77M | $3.38B | 96.71% | 66Neutral |
 ANRO | Alto Neuroscience, Inc. | 1.31% | $5.13M | $957.90M | 117.65% | 42Neutral |
 FEIM | Frequency Electronics | 1.31% | $5.11M | $768.73M | 78.55% | 76Outperform |
 VCTR | Victory Capital Holdings | 1.23% | $4.81M | $6.71B | 66.42% | 80Outperform |
 ORKA | Oruka Therapeutics | 1.23% | $4.81M | $5.24B | 204.50% | 41Neutral |
 ADPT | Adaptive Biotechnologies | 1.20% | $4.70M | $3.90B | 48.39% | 53Neutral |
 DXPE | DXP Enterprises | 1.09% | $4.27M | $2.75B | 36.30% | 71Outperform |
 AEHR | Aehr Test Systems | 1.08% | $4.21M | $2.09B | 135.01% | 55Neutral |
 INBX | Inhibrx Biosciences Inc | 1.13% | $4.43M | $1.45B | 208.06% | 62Neutral |
DWAS Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DWAS, the sentiment is Neutral. The current price of 103.74 is below the 20-day moving average (MA) of 106.43, below the 50-day MA of 109.69, and below the 200-day MA of 109.10, indicating a bearish trend. The MACD of -1.83 indicates Positive momentum. The RSI at 45.13 is Neutral, neither overbought nor oversold. The STOCH value of 46.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DWAS.
DWAS Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| DWAS | $103.74 | $115.00(10.86% Upside) | $388.57M | 0.60% | 62Neutral |
 SFLO | $40.16 | $47.59(18.50% Upside) | $859.96M | 0.49% | 68Neutral |
 OUSM | $48.87 | $54.37(11.25% Upside) | $807.71M | 0.48% | 72Outperform |
 BBSC | $85.20 | $110.48(29.67% Upside) | $726.82M | 0.09% | 63Neutral |
 EES | $66.12 | $80.55(21.82% Upside) | $683.96M | 0.38% | 67Neutral |
 JHSC | $46.80 | $57.49(22.83% Upside) | $682.57M | 0.42% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DWAS | Invesco DWA SmallCap Momentum ETF | 103.74 | 8.40 | 8.81% | |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 40.16 | 11.38 | 39.54% | |
| OUSM | OShares U.S. Small-Cap Quality Dividend ETF | 48.87 | 5.29 | 12.15% | |
| BBSC | JPMorgan BetaBuilders U.S. Small Cap Equity ETF | 85.20 | 9.67 | 12.81% | |
| EES | WisdomTree U.S. SmallCap Fund | 66.12 | 10.45 | 18.77% | |
| JHSC | John Hancock Multifactor Small Cap ETF | 46.80 | 4.86 | 11.59% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.